A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Azithromycin (Primary) ; BPZE 1 (Primary)
- Indications Pertussis
- Focus Therapeutic Use
- Acronyms CHAMPION-1
- Sponsors ILiAD Biotechnologies
Most Recent Events
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 Sep 2023 According to ILiAD Biotechnologies media release, primary data from this study study will be presented at the World Vaccine Congress on October 19th in Barcelona.
- 05 Sep 2023 According to ILiAD Biotechnologies media release, Primary endpoint (Colonisation following Virulent Challenge) has been met.